Vibrato Medical Closes $4M Series A Funding Round and Receives $1.5M NIH Grant
- Vibrato Medical
MONTIRVINE, Calif.–(BUSINESS WIRE)–Vibrato Medical, an innovator in the treatment of peripheral arterial disease (PAD), announced today that it has closed a $4M Series A funding round led by the Horowitz Group, a multi-asset class family investment office based in Newport Beach, CA, and has also received a $1.5M National Institutes of Health (NIH) grant. Together, funding will support the clinical trial of the company’s novel, noninvasive, wearable device designed to treat patients with critical limb ischemia (CLI), an advanced stage of PAD, from the convenience of their home. Read more…
Related Reading
Blog / Diagnostics / Government & Legislative Affairs / Health Access / Regulatory Affairs
Fixing Medicare’s Lab Payment System: Why the RESULTS Act Matters
November 18, 2026
Clinical laboratory tests are critical to how clinicians screen for disease, diagnose conditions, guide treatment, and monitor outcomes for patients with diabetes, cancer, heart disease, and more.
Blog / Government & Legislative Affairs / Health Access / Regulatory Affairs
Protecting Patient Access to Ostomy and Urological Supplies
November 18, 2026
For roughly one million Americans, ostomy and urological supplies are essential. Whether it is from a condition at birth, result of injury or trauma, or cancer- these products replace or support lost bowel and bladder function. Because they are so personal, each product must match a patient’s anatomy, skin, and daily needs. A poor fit or faulty product can easily lead to leakage, skin breakdown harming a person, and reduced quality of life. If these issues aren’t addressed-the problems compound leading to infection, and hospitalization.
Resource / Government & Legislative Affairs / Health Access / Regulatory Affairs
U.S. Evidence Snapshot: Medtech Saves Lives
November 17, 2026
U.S. life expectancy has reached its highest level in history. Age-adjusted death rates for the leading causes of death dropped from 2023 to 2024, according to preliminary CDC data.
Resource / Artificial Intelligence (AI) / Regulatory Affairs
Comments on FDA’s PMA eSTAR Draft Guidance
November 17, 2026
In this AdvaMed® Comment Letter to FDA, AdvaMed responds to the agency’s draft guidance on the electronic submission template (eSTAR) for premarket approval (PMA) applications. With eSTAR set to become mandatory for PMAs, AdvaMed calls for a template that keeps today’s flexibility, handles large files, and is built and updated through a clear, open, and predictable process. These changes would help medtech companies prepare complete submissions and help FDA review them more efficiently.
Resource / Digital Health / Global & Trade / Regulatory Affairs
EY Pulse of the MedTech Industry Report 2026
November 5, 2026
The 20th edition of the EY Pulse of the MedTech Industry Report captures the medical devices sector at both a high point and a turning point.
Resource / Government & Legislative Affairs / Regulatory Affairs
Justin Klein Op-Ed: CMS Can Make RAPID a Win for Patients and American Medtech Innovation
November 5, 2026
In this op-ed published in Medtech Insight, Justin Klein, MD, JD, explains how the proposed RAPID coverage pathway could accelerate Medicare access to breakthrough medical technologies and why targeted refinements are essential to its success.
News / Digital Health / Health Access / Regulatory Affairs
AdvaMed Digital Health Tech Board Approves Best Practices to Advance Responsible Data Access and Patient Care
October 28, 2026
WASHINGTON, D.C.—AdvaMed, the Medtech Association, today announced that its Digital Health Tech Board of Directors has approved voluntary Data Access Principles & Best Practices to help medical technology companies and health systems collaborate on responsible data access, use, and protection. The framework puts patient trust at the center of efforts to improve care, support research, and advance innovation, including artificial intelligence.
Event / Regulatory Affairs
When MedTech Meets Connectivity: The Hidden Risk from Standard-Essential Patents (SEPs) — and How to Navigate It
November 11, 2026
1:00 PM
Join McDermott Will & Schulte Law in this session that will explore explore practical guidance for companies developing connected medical technologies navigating SEPs, FRAND licensing and patent pools.